Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name EML4 - ALK AXL over exp
Gene Variant Detail

AXL over exp (no effect)

EML4 - ALK (gain of function)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
EML4 - ALK AXL over exp lung adenocarcinoma predicted - sensitive Bemcentinib + Crizotinib Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) and Xalkori (crizotinib) combination treatment did not induce apoptosis, however, inhibited proliferation of Xalkori (crizotinib)-resistant lung adenocarcinoma cells harboring EML4-ALK and overexpressing AXL in culture (PMID: 32558295). 32558295
EML4 - ALK AXL over exp lung adenocarcinoma no benefit Bemcentinib Preclinical - Cell culture Actionable In a preclinical study, Xalkori (crizotinib)-resistant lung adenocarcinoma cells harboring EML4-ALK and overexpressing AXL did not demonstrate sensitivity to Bemcentinib (BGB-324) treatment in culture (PMID: 32558295). 32558295
EML4 - ALK AXL over exp lung non-small cell carcinoma resistant Alectinib Preclinical - Cell line xenograft Actionable In a preclinical study, Alecensa (alectinib) failed to inhibit cell growth, phosphorylation of Alk and Axl, or downstream signaling in a non-small cell lung cancer cell line harboring EML4-ALK and overexpressing AXL in culture, and did not inhibit tumor growth in cell line xenograft models (PMID: 33627640). 33627640
EML4 - ALK AXL over exp lung non-small cell carcinoma sensitive Gilteritinib Preclinical - Cell line xenograft Actionable In a preclinical study, Xospata (gilteritinib) inhibited cell growth, phosphorylation of Alk and Axl, and downstream signaling in a non-small cell lung cancer cell line harboring EML4-ALK and overexpressing AXL in culture and suppressed tumor growth in cell line xenograft models and inhibited tumor growth when administered to separate xenograft models that had previously demonstrated resistance to Alecensa (alectinib) treatment (PMID: 33627640). 33627640